KEYNOTE-061: Phase III Trial of Second-line Pembrolizumab vs Paclitaxel in Previously Treated, Unresectable Gastric or Gastroesophageal Junction Cancer

June 1-5, 2018; Chicago, Illinois
Final analysis of phase III trial showed no significant improvement with pembrolizumab vs paclitaxel in OS, PFS, or response in patients with previously treated gastric/GEJ cancer and PD-L1 CPS ≥ 1.
Format: Microsoft PowerPoint (.ppt)
File Size: 225 KB
Released: June 12, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Module from Clinical Care Options (CCO): Christine Chio, PharmD, BCOP; Lipika Goyal, MD; and Caroline Kuhlman, NP, discuss current treatment of cholangiocarcinoma, including the use of biomarkers

Christine Chio, PharmD, BCOP Lipika Goyal, MD Caroline Kuhlman, NP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 13, 2022 Expired: May 12, 2023

Review this slideset on the current treatment of cholangiocarcinoma with expert perspectives from Christine Chio, PharmD, BCOP; Lipika Goyal, MD; and Caroline Kuhlman, NP.

Christine Chio, PharmD, BCOP Lipika Goyal, MD Caroline Kuhlman, NP Released: May 13, 2022

On-demand webcast on HER2, HER3, and TROP2 antibody-drug conjugates in breast, gastrointestinal, and lung cancers, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Yelena Y. Janjigian, MD Sandip P. Patel, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

Multidisciplinary commentary on optimal use of HER2-targeted treatment in early and metastatic breast cancer, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Kristi Kay Orbaugh, MSN, NP, AOCNP Danielle Roman, PharmD, BCOP Released: May 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings